Alembic Pharmaceuticals Management Guidance Tracker

Management expects US business to grow 10-12% for the full year FY26, driven by volume growth and new launches.

Management targets low double-digit topline growth for FY27 at consolidated level.

Management expects India branded business growth to converge with the market growth rate by Q1 of the next financial year.

R&D investments expected to be around ₹750-800 crore, focusing on complex and peptide developments.

Full-year R&D spend guidance of ₹600-650 crore, representing 8-9% of revenue.

First branded product Pivya to be launched in the US in Q4 FY26, with prescription share scaling over 12-18 months.

With Pivya launch, branded franchise expected to reach meaningful revenue profile in next few quarters.

Capital expenditure guided at ₹300-350 crore, primarily for capacity debottlenecking and replacement.